BioNTech SE has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024. She will join BioNTech from Novartis succeeding Sean Marett in this role.
 
Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access. In her new role, she will drive the company’s global commercialization strategy. Annemarie Hanekamp will be responsible for building a global commercial team in preparation of BioNTech’s first oncology product launch planned in 2026 and with a focus on its lead product candidates in anticipation of ten potential indication approvals by 2030.
 
“Annemarie Hanekamp is an accomplished leader with a track record of more than a dozen successful product launches, including first-time product launches in the solid tumor field across multiple cancer types relevant to BioNTech, such as lung, breast, gastrointestinal, prostate and bladder,” said Helmut Jeggle, Chairman of the Supervisory Board. “She brings a deep understanding of commercialization of oncological products in the U.S. as well as in key markets in Europe. We look forward to welcoming Annemarie Hanekamp to the Management Board as we continue our work towards improving treatment options for patients and providers.”
 
Annemarie has more than 20 years of experience in the healthcare industry, including 15 years of commercial experience in companies ranging from early-stage biotechnology companies to full-scale pharmaceutical companies. At Novartis, she led the U.S. and global teams through a time of strategic opportunities and operational headwinds following a strong launch uptake of their novel treatment for prostate cancer. She was also responsible for building a new global oncology organization following a company-wide transformation. At Bristol-Myers Squibb, she held a pivotal role in evolving the company’s U.S. oncology strategy, resulting in significant and sustainable growth including an expanded market access as well as product launches.